Skye Bioscience

SKYE

Market cap $47.4M

NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Skye Bioscience stock nosedives 60% after its investigational obesity candidate, nimacimab, fails to meet the key goal in a mid-stage study.

Skye Bioscience, Inc. - Special Call Company Participants Bernie Hertel Punit Dhillon - President, CEO, Secretary & Director Puneet Arora - Chief Medical Officer Tu Diep - Chief Operating Officer Christopher Twitty - Chief Scientific Officer Conference Call Participants Jay Olson - Oppenheimer & Co. Inc., Research Division Louis Aronne Michael DiFiore - Evercore ISI Institutional Equities, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Sean Wharton Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division Gum-Ming Lowe - Craig-Hallum Capital Group LLC, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Ananda Ghosh - H.C.

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 150 points on Monday.

Skye Bioscience Inc. (NASDAQ:SKYE) stock sank on Monday after the company released topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab.

Skye Bioscience said on Monday its experimental obesity drug did not meet the main goal of a mid-stage study.

Nimacimab monotherapy did not meet its primary endpoint for weight loss; preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy. Clinically meaningful additional weight loss observed with combination of nimacimab, a peripheral CB1 inhibitor, and semaglutide compared to semaglutide alone.

Skye Bioscience is rated Buy, driven by nimacimab's strong safety, durable weight-loss profile, and upcoming Phase 2a results. SKYE's nimacimab targets the expanding anti-obesity market, showing potential as monotherapy, combination, or maintenance therapy, with favorable early data. Risks include clinical trial uncertainties, manufacturing reliance, and regulatory scrutiny, but SKYE's cash runway extends through Q1 2027, supporting key milestones.

On Friday, Skye Bioscience, Inc. SKYE announced the presentation of results from the Phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease (MASLD) at the European Association for the Study of Diabetes (EASD) Annual Meeting.